Clinical Trials Browser

Phase 2 × Lung Neoplasms × Hematologic Tests × Clear all

NCT06620835 2025-07-29

OPTALK

Phase 2 Recruiting

Lung Neoplasms

NCT02839681 2019-05-21

Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma

Phase 2 Terminated

2 enrolled 12 charts

Adenocarcinoma of Lung, Lung Neoplasms